Molecular Cancer
Scope & Guideline
Unlocking the secrets of cancer biology and treatment.
Introduction
Aims and Scopes
- Molecular Mechanisms of Cancer:
The journal explores the intricate molecular pathways that contribute to cancer development, progression, and metastasis, including genetic mutations, epigenetic modifications, and signaling pathways. - Cancer Immunology and Immunotherapy:
A significant focus is on the immune system's role in cancer, including the mechanisms of immune evasion by tumors and the development of innovative immunotherapeutic strategies. - Non-coding RNAs and Circular RNAs:
Research on non-coding RNAs, particularly circular RNAs, is a core area, examining their roles in gene regulation, tumor progression, and potential as therapeutic targets. - Tumor Microenvironment and Metabolism:
The journal investigates the relationship between tumor cells and their microenvironment, including the metabolic reprogramming of cancer cells and the influence of stromal components on tumor behavior. - Liquid Biopsy and Biomarkers:
There is a strong emphasis on the development and validation of biomarkers for cancer diagnosis, prognosis, and treatment response, particularly through liquid biopsy technologies. - Targeted and Personalized Therapies:
Research on targeted therapies, including small molecules and biologics, is prevalent, focusing on identifying actionable mutations and developing personalized treatment approaches. - Translational and Clinical Research:
The journal aims to bridge basic research with clinical applications, promoting studies that translate laboratory findings into therapeutic strategies for cancer patients.
Trending and Emerging
- Circular RNAs and Their Therapeutic Potential:
Research on circular RNAs has surged, exploring their mechanisms in cancer biology and their potential as therapeutic targets and biomarkers. - Multi-Omics Approaches:
There is a growing trend towards integrating multi-omics analyses (genomics, transcriptomics, proteomics) to better understand cancer heterogeneity and inform personalized therapies. - Cancer Immunometabolism:
The intersection of cancer metabolism and immunology is gaining traction, with studies focusing on how metabolic pathways influence immune responses in the tumor microenvironment. - CRISPR and Gene Editing Technologies:
The application of CRISPR and other gene editing technologies in cancer research is rapidly expanding, focusing on their potential to create novel therapies and understand gene function in cancer. - Liquid Biopsy Innovations:
Innovative approaches to liquid biopsy are emerging, with research targeting circulating tumor DNA and exosomal RNA as non-invasive methods for cancer detection and monitoring. - Targeting the Tumor Microenvironment:
There is an increasing emphasis on understanding and targeting the tumor microenvironment, particularly the roles of cancer-associated fibroblasts and immune cells in tumor progression and therapy resistance. - Combination Therapies and Personalized Medicine:
Research is increasingly focused on combination therapies that leverage advances in genomics and immunotherapy, aiming for personalized treatment strategies that improve patient outcomes.
Declining or Waning
- Traditional Chemotherapy Mechanisms:
There has been a noticeable decrease in publications focusing solely on traditional chemotherapy mechanisms, as the field shifts towards exploring combination therapies and personalized approaches. - Basic Cancer Genetics without Functional Insights:
Research that merely catalogs genetic mutations in cancers without functional validation or therapeutic implications is less frequently seen, as the emphasis has shifted to understanding the functional consequences of these mutations. - In vitro Studies with Limited Clinical Relevance:
Studies that focus solely on in vitro models without robust links to clinical outcomes or translational potential are becoming less prevalent, as researchers prioritize more clinically relevant models. - Single-Target Therapies:
Interest in single-target therapies has waned, with a growing focus on combination therapies and multi-target strategies that address the complexity of cancer biology. - Historical Cancer Treatments:
Research centered on older treatment modalities without novel insights or improvements has decreased, as the field moves towards innovative therapies and precision medicine.
Similar Journals
Advances in Cancer Biology-Metastasis
Pioneering Pathways in Cancer Research.Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.
Journal of Hematology & Oncology
Pioneering Discoveries in Hematology and OncologyJournal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
Exploring breakthroughs in therapeutic strategies.International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.
ANTICANCER RESEARCH
Advancing the Frontiers of Cancer ResearchANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.
CANCER SCIENCE
Leading the charge in innovative cancer treatment solutions.Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.
Annual Review of Cancer Biology
Illuminating Breakthroughs in Cancer BiologyAnnual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.
CANCER GENE THERAPY
Driving Progress in Molecular Biology for Cancer SolutionsCancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.
Blood Cancer Discovery
Pioneering Discoveries for a Cancer-Free TomorrowBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.
CANCER INVESTIGATION
Illuminating pathways in oncology through peer-reviewed excellence.CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.
Cancer Cell International
Elevating the Standards of Cancer ResearchCancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.